Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms.

This non-diversified fund may invest a substantial portion of assets in equity securities of smaller capitalization companies with a market capitalization of less than $1.5 billion.

Gilead Sciences Inc. (GILD), Celgene Corp. (CELG) and Genzyme Corp. (GENZ) are among the fund’s key holdings.

Templeton Developing Markets A (TEDMX) seeks long-term capital appreciation through investment in securities of emerging economies.

The fund may invest up to 20% of net assets in the securities of issuers in developed market countries. It may also invest in exchange-traded funds to gain exposure to certain segments of the equity markets while maintaining liquidity.

J. Mark Mobius has been lead manager at the fund since October 1991. The fund distributes dividends and capital gains, if any, annually.

Click here to see all the mutual funds offered by Matthews International.

Zacks Investment Research

Last 5 posts by Zacks Market Commentaries

• Biogen Beats & Guides Higher - Analyst Blog - February 9th, 2010
• Becton Recalls Catheters - Analyst Blog - February 9th, 2010
• CRK Misses on Lower Gas Prices - Analyst Blog - February 9th, 2010
• Molson Coors Misses Expectations - Analyst Blog - February 9th, 2010
• UBS Profits, Outflows Continue - Analyst Blog - February 9th, 2010